



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville MD 20857

APR - 6 1998

Re: EXCENEL sterile suspension[®]
Docket No. 96E-0269

#22

Stephen G. Kunin
Deputy Assistant Commissioner for
Patent Policy and Projects
Office of the Assistant Commissioner for Patents
U.S. Patent and Trademark Office
Crystal Park Building 2, Suite 919
Washington, DC 20231

RECEIVED

APR 17 1998

**PATENT EXTENSION
A/C PATENTS**

Dear Mr. Kunin:

This is in regard to the patent term extension application for U.S. Patent No. 4,902,683 filed by Pharmacia & Upjohn Company under 35 U.S.C. § 156. The patent claims the animal drug product EXCENEL sterile suspension[®] (ceftiofur hydrochloride), New Animal Drug Application NADA 140-890.

In the February 28, 1997, issue of the Federal Register (62 Fed. Reg. 9195), the Food and Drug Administration published its determination of this product's regulatory review period, as required under 35 U.S.C. § 156(d)(2)(A). The notice provided that on or before August 27, 1997, 180 days after the publication of the determination, any interested person could file a petition with FDA under 35 U.S.C. § 156(d)(2)(B)(i) for a determination of whether the patent term extension applicant acted with due diligence during the regulatory review period.

The 180-day period for filing a due diligence petition pursuant to this notice has expired and FDA has received no such petition. Therefore, FDA considers the regulatory review period determination to be final.

Please let me know if we can provide further assistance.

Sincerely yours,

Ronald L. Wilson, Director
Health Assessment Policy Staff
Office of Health Affairs

cc: Martha A. Gammill
Pharmacia & Upjohn
Intellectual Property Services
301 Henrietta St.
Kalamazoo, MI 49001